Search

Your search keyword '"Soufer, J"' showing total 17 results

Search Constraints

Start Over You searched for: Author "Soufer, J" Remove constraint Author: "Soufer, J"
17 results on '"Soufer, J"'

Search Results

1. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

2. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

3. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

4. Dapagliflozin and cardiovascular outcomes in type 2 diabetes

5. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

6. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

7. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial

8. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

9. Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

10. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

11. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

12. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

13. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME (R) trial

14. Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone

15. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

16. High-strength capsaicin cream 0.25% in a lidocaine-containing vehicle (Axsain) is a safe and effective adjunctive treatment for painful diabetic neuropathy or postherpetic neuralgia.

17. Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.

Catalog

Books, media, physical & digital resources